NCT04596943View on ClinicalTrials.gov

RGD PET/CT Imaging in COVID-19 Patients

CompletedOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

October 15, 2020

Primary Completion Date

February 1, 2021

Study Completion Date

March 1, 2021

Conditions
Covid19Endothelial DysfunctionPET Imaging
Interventions
DIAGNOSTIC_TEST

[68Ga]Ga-DOTA-(RGD)2 PET/CT

We have developed a dimeric cyclic RGD peptide conjugated with DOTA as a chelator. If labeled with the positron emitting radionuclide Gallium-68 (68Ga), \[68Ga\]Ga-DOTA-(RGD)2 can be used to visualize αvβ3 integrin expression with PET

Trial Locations (1)

6500HB

Radboudumc, Nijmegen

All Listed Sponsors
lead

Radboud University Medical Center

OTHER

NCT04596943 - RGD PET/CT Imaging in COVID-19 Patients | Biotech Hunter | Biotech Hunter